Home > News > Latest > EASL: Bristol-Myers' drug cuts liver fat in NASH

EASL: Bristol-Myers' drug cuts liver fat in NASH

In a late-breaking oral presentation on Saturday at the International Liver Congress (EASL), held in the Netherlands, Bristol-Myers Squibb unveiled Phase 2 data from the study of BMS-986036, its pegylated analog of human fibroblast growth factor (FGF21).

Spotlight

Other News

Dom Nicastro | April 03, 2020

Dom Nicastro | April 03, 2020

Dom Nicastro | April 03, 2020

Dom Nicastro | April 03, 2020

More Trending news

Spotlight

Resources

Introducing EU Annex 1: Understanding the Newest Regulatory Requirements

Whitepaper

Driving Down Drug Costs: How Real-Time Transparency in PBMs Can Make a Difference

Article

How long will the world wait for the next pandemic of antimicrobial resistance before we act?

Article

Introducing EU Annex 1: Understanding the Newest Regulatory Requirements

Whitepaper

Driving Down Drug Costs: How Real-Time Transparency in PBMs Can Make a Difference

Article

How long will the world wait for the next pandemic of antimicrobial resistance before we act?

Article